IN THE PIPELINE

OHSL has forges numerous partnerships between researchers and research institutions around the world. The following are just a few examples:

  1. Blockchain Technology for Pharmaceutical Supply Chain and Virtual Clinical Trials

While blockchain is most notably used in the financial sector to keep track of cryptocurrency such as bitcoin, blockchain is increasingly being used in other sectors, particularly in monitoring the movements of various types of products through their supply chains. Blockchain has also been proposed by several organizations as a possible solution for keeping counterfeit medicines out of the pharmaceutical supply chain. OHSL and its partners are developing competency in the use of blockchain and are working within a consortium to develop a patient-centered pharmaceutical supply system that utilizes blockchain technology to monitor the movement of pharmaceuticals in developing countries, from manufacturer to patient.

In addition, OHSL is exploring the possibility of employing blockchain technology to enhance the security and accountability within clinical trials. OHSL is currently looking for partners in the clinical research world who can work with us in developing this activity.

  1. Repurposing Niclosamide for Colon Cancer 

OHSL partnered with Duke University’s Cancer Center and Tata Memorial Center to reformulate and repurpose Niclosamide as a colon cancer therapeutic. Niclosamide is an off-patent drug previously used to cure tapeworm disease. OHSL is working to identify the research partner and pharmaceutical manufacturer to bring this drug to a new patient population. The consortium has completed pre-clinical studies, and is now proceeding to the clinical trials phase. This is an ongoing project over two years with approximately USD $7 Million of grant funding from NIH.

  1. Radiation Sensitizers

This project took certain off-patent drugs that, when administered with radiation, improves the efficacy of the radiation and the efficacy of treatment.  This international consortium was led by OHSL, and included:

  • India Institute of Technology in New Delhi, India
  • The Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), supported by the Indian Department of Atomic Energy, located in Mumbai, India
  • India’s Institute of Nuclear Medicine & Allied Sciences (INMAS) within India’s (DRDO) Defense Research and Development Organization in New Delhi, India
  • Adyar Cancer Institute in Chennai, India

OHSL created, launched, and is currently coordinating this effort.  Project is valued at $2M over 1 year, and will likely be extended.

  1. Connectivity and Capacity Building for Cancer Research

OHSL created and launched a successful international consortium to build clinical trial units in Pakistan, and build a new National Cancer Grid in India to connect 54 cancer centers throughout the country to one another, and also to promote capacity building and research in cancer.

Duke University provided training for the development and operation of the clinical trial units at Aga Khan University Hospital in Karachi.  This was a 2-year project and cofounded by the existing partners and NIH, and valued at USD $11.5 Million.